Symptomatic SMA newborns/infants with 4 copies of SMN2: considering the phenotypic variability that can be associated with 4 copies of SMN2, it is advisable to start treatment with Risdiplam or Nusinersen (31). Here, SMN2 is linked to proximal spinal muscular atrophy.